Beyond capabilities: What biotech leaders should really look for in a clinical development partner

When biotech companies evaluate drug development partners, early conversations are often centered on the obvious factors: therapeutic expertise, geographic reach, delivery model and cost. Biotech leaders are also increasingly recognizing that areas such as endpoint strategy and patient-centered data collection can reveal how effectively a partner will think, adapt and solve problems alongside them once a study is underway. All of these factors are important, but once a shortlist is made and multiple providers can meet the basic requirements, the real differentiator is often something less visible: fit

This relationship is not a short transaction—it’s a working partnership that lasts for years through uncertainty, course correction and operational pressure. How well will this group listen, adapt, communicate, challenge assumptions and work through surprises over the life of a drug development program?

Answers to these questions matter more than many companies realize and are increasingly important in our current environment. In biotech, the stakes are rarely limited to a single workstream. Delays can affect funding milestones, partnership plans, internal credibility and key timelines. A CRO relationship that looks solid in a proposal can still create friction if the day-to-day partnership is rigid, transactional or misaligned with how a biotech team actually operates.

Capabilities get shortlisted. Alignment determines whether the partnership works.

Many biotech teams are lean, wearing multiple hats, moving fast and managing competing demands with limited margin for error. They need more than just execution from a CRO. They need a partner who can think alongside them, pivot when priorities shift, challenge assumptions and help them navigate complexity—not add to it.

A poor fit tends to show up first in subtle ways. Communication may feel formulaic, risks may be raised too late and scope of conversations may seem rigid. The team might answer the question they expected instead of the one the sponsor asked. Over time, a poor fit becomes more serious, resulting in team turnover, knowledge transfer burden, timeline disruption or the need to move a clinical study elsewhere. These are expensive distractions for organizations already under pressure to move with confidence.

What to look for beyond the checklist

The most overlooked differentiator in CRO selection is often the simplest one: people.

The first signal is how the team interacts before work begins.

Are they actively listening, or simply reciting what they have done before?

Do they tailor their answers to your study and operational reality?

Are they willing to challenge assumptions constructively, or are they trying to win the work by agreeing with everything?

A strong indicator of fit is whether a CRO team can engage in real dialogue, pressure-test ideas, and show thoughtful adaptation rather than simply revising a budget and calling that flexibility.

Biotechs should also pay attention to how a potential partner talks about processes. In a regulated environment, discipline matters. But there is a difference between having strong processes and being trapped by them. The right partner can work within robust standards while still interpreting them in ways that fit the needs of a specific program. Flexibility, in other words, is not the absence of rigor. It is the ability to apply rigor intelligently.

Three perspectives biotech teams should weigh

Business leaders: Look for long-term value

Cost matters, but low initial cost does not always equal low risk. Business leaders should ask whether a partner understands the broader commercial context around the asset. A strong partner is not just selling labor. They are empowering a biotech think through risk, scalability, and the downstream impact of today’s decisions, including being able to support the asset as it progresses.

Scientific leaders: Look for intellectual engagement

For scientific teams, the most important soft factor may be intellectual engagement. They need a CRO that goes beyond task execution and understands the science, treatment paradigms, endpoint strategy, and increasingly important approaches to patient-centered and digital data collection well enough to engage credibly, challenge thoughtfully, and fill gaps without creating friction.

Operations leaders: Look for access

Operational fit starts with the right team to deliver your program, on time, at top quality and within budget. However, it also comes down to how quickly issues can be addressed and how easy it is to reach the right people. Lean biotech teams do not have time for layers of bureaucracy. They need direct connections, clear escalation pathways and a team that engages immediately after award.

A better way to evaluate fit

Biotech companies should treat partner selection less like a procurement exercise and more like a test of how the relationship will function under pressure. Ask for one-on-one conversations with the people who will run the study day to day. Challenge them a bit. See how they respond when the answer is not obvious. Pay attention to whether they push back thoughtfully, admit what they do not know and follow through on what they say. The goal is not perfection, but evidence of partnership behavior.

For biotech leaders, that may be the most important takeaway: capabilities are necessary, but they are not sufficient on their own. The right provider of clinical research solutions is not just qualified to do the work. They are structured and staffed to enable a biotech to move faster, make better decisions and navigate change without losing momentum.

Many biotech companies are increasingly looking for partners that combine scale with a biotech mindset: teams that bring depth and reach, but still work in a flexible, direct and highly engaged way. That is the standard biotechs should expect, and the model the PPD™ clinical research business of Thermo Fisher Scientific delivers.